Navigation Links
Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study
Date:10/18/2010

ight dose of Intermezzo®.  A secondary analysis that evaluated mean differences in SDLP between Intermezzo® and placebo administered three hours prior to driving showed a difference of 1.5 cm, which was statistically significant.

Driving data: 9 hours after dosing zopiclone at bedtime, the active controlZopiclone was studied to establish that the test design was capable of detecting driving impairment.  Zopiclone worked as expected, confirming the ability of the study to detect such impairment. The symmetry analysis showed statistically significant drug effect on driving performance in healthy subjects who began driving an automobile nine hours after receiving zopiclone at bedtime.  The mean difference in SDLP between zopiclone and placebo administered nine hours prior to driving showed a difference of 2.5 cm, which was statistically significant.

Three drives were terminated prematurely during the study due to excessive sleepiness.  One subject failed to complete two drives, one on the zopiclone treatment arm, the active control in the study, and the other on the Intermezzo® 3-hour treatment arm. A second subject failed to complete the drive in the zopiclone treatment arm.

Glenn A. Oclassen, Transcept President and Chief Executive Officer, said, "The findings from this highway driving study reinforce our belief that Intermezzo® has the potential to be the first FDA approved sleep medication for use as needed when a  middle of the night awakening is followed by difficulty returning to sleep.  If approved by the FDA, these results will further differentiate Intermezzo® from other sleep aids by providing physicians and their patients with important safety information from what we believe to be the largest highway driving study of its kind. This study is a central component of our broader resubmission strategy to address the concerns expressed by the FDA in
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Transcept Pharmaceuticals to Host Conference Call to Discuss Preliminary Analysis of Intermezzo® Highway Driving Study
2. Transcept Pharmaceuticals to Present at Newsmakers in the Biotech Industry Conference
3. Transcept Pharmaceuticals to Present at BIO Investor Forum
4. Transcept Pharmaceuticals to Present at UBS Global Life Sciences Conference
5. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
6. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
7. Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter
8. Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
10. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
11. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Alemania, December 17, 2014 ... anterior, con un alto nivel de gasto en investigación ... fiscal 2013/14 (finalizado el 30 de septiembre de 2014) ... a 4.287 millones de euros (año anterior: 4.190 millones ... moneda desfavorables. Las ganancias (EBIT) crecieron un 14 por ...
(Date:12/17/2014)... 2014  Strategic Health Services, Inc. (SHS), a leading ... a strategic agreement with QualCare, Inc., a leading provider of ... regional marketplace.  This agreement will further QualCare,s population ... solutions QualCare brings to its clients in ... QualCare plans cover more than 800,000 member ...
(Date:12/17/2014)... YORK , Dec. 17, 2014 ... imaging (MRI), the MRI market is seeing new ... and breast MRI scans account for the majority ... a higher resolution of images, which are creating opportunities ... imaging (MRI) market is growing at a rate ...
Breaking Medicine Technology:ZEISS confirma su posición en un entorno difícil 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3
... Ferring Pharmaceuticals presented an interim study analysis indicating that ... in vitro fertilization (IVF) cycles using a gonadotropin-releasing ... poster at the 65th Annual Meeting of the American ... 2009. , MENOPUR® vs. rFSH in ...
... NANJING, China, Oct. 20 /PRNewswire-Asia/ -- ... the "Company"), a leading pharmaceutical company,specializing in development, ... in China, today announced an agreement with,OSI Pharmaceuticals, ... OSI-930 in China. , ...
Cached Medicine Technology:Research Compares MENOPUR(R) With rFSH in GnRH Antagonist IVF Cycles 2Research Compares MENOPUR(R) With rFSH in GnRH Antagonist IVF Cycles 3Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals 2Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals 3
(Date:12/20/2014)... Columbus, OH (PRWEB) December 20, 2014 ... contend they suffered uncontrollable bleeding and other ... District Court, Eastern District of Louisiana for coordinated pretrial ... Panel on Multidistrict Litigation (JPML) issued an order Friday ... tag-along actions pending in 22 federal courts to the ...
(Date:12/19/2014)... It’s very easy to become overwhelmed with the ... to the wayside until Christmas and the New Year are ... and that burning desire to just escape it all and ... to Telluride with a no-fuss, affordable package. Montrose Days Inn ... resort, and ensure that all accommodations are met. Plus, everyone ...
(Date:12/19/2014)... Branson, Missouri (PRWEB) December 19, 2014 ... a new official world record -- for the first time ... most prestigious record book, Guinness World Records 2015, listing the ... Steepest Wooden Roller Coaster. In additional awards announced this week, ... to See Christmas Lights in the US,” USA Today’s 10Best ...
(Date:12/19/2014)... The Medspa at Hendrick in Abilene, TX ... cosmetic brand Juvéderm. Voluma XC treats volume loss in ... at Hendrick is pleased to be able to offer ... its clients. , Voluma is the first and only ... the mid-face and cheek area. This non-invasive treatment targets ...
(Date:12/19/2014)... 19, 2014 (HealthDay News) -- Potentially illness-causing E. coli ... at farmers markets, according to a new study. ... vendors from 13 farmers markets in Los Angeles and ... Out of almost 150 samples tested, 24 percent were ... salmonella, according to the researchers. Both types of ...
Breaking Medicine News(10 mins):Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Silver Dollar City Nets New Titles: Guinness Book of World Records, Plus CNN Travel, USA Today & Fodor’s Top Places for Christmas Lights 2Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2Health News:E. Coli Germs Found on Farmers Market Herbs 2
... too closely to pacemakers, ICDs , , SUNDAY, Nov. 9 ... into your coat pocket might not be exactly heart-stopping, ... your implanted cardiac device. , Harvard researchers ... sessions, in New Orleans, report that magnets in these ...
... The NHS Human,Services Foundation held its fifth annual Leading ... Regency Penn,s Landing in Philadelphia. This event is,one of ... mission,of NHS Human Services, one of the largest providers ... year the Foundation presents the Leading the Way Award ...
... The 2008 Joint Meeting of the American Academy of ... the largest and most comprehensive ophthalmic educational meeting in ... to 11 at the Georgia World Congress Center, Atlanta. ... "Breakfast with the Experts" roundtables, 95 skills transfer courses, ...
... Surgery Patients can Better Understand Their Condition at CataractSurgery.com , ... ... surgery patients and their caregivers now have a new online educational ... Cataracts affect nearly 20 million Americans age 60 and ...
... uric acid in dog breed , , FRIDAY, Nov. 7 (HealthDay ... of uric acid that lead to bladder stones in Dalmatians ... may provide clues about kidney stones in humans. , Among ... of uric acid in their urine and blood. Other dog ...
... treating colorectal cancer varies widely, with newer, life-extending therapies ... older agents, according to a study led by a ... , "The total cost of chemotherapy to treat colorectal ... patient, depending on the regimen," said Gary Lyman, M.D., ...
Cached Medicine News:Health News:MP3 Player Headphones May Throw Off Cardiac Devices 2Health News:MP3 Player Headphones May Throw Off Cardiac Devices 3Health News:Gala Raises Funds for NHS Human Services 2Health News:AAO-SOE Joint Meeting research highlights 2Health News:AAO-SOE Joint Meeting research highlights 3Health News:AAO-SOE Joint Meeting research highlights 4Health News:Alcon Sponsors Online Educational Initiative for Patients Considering Cataract Surgery 2Health News:Gene Mutation in Dalmatians Sheds Light on Kidney Stones in Humans 2Health News:Cost of treating colorectal cancer can vary by thousands per patient 2
... double lumen tube made of silicone rubber with ... to the characteristics of silicone rubber, Silbronco is ... insertion. Furthermore, the tube will not soften like ... term surgery., ,Silbronco is also especially useful ...
The Pedia-Trake® is designed to reduce the possibility of over penetration., ,Pedia-Trake® is used to establish an emergency airway in pediatric patients more than one year old....
Used for emergency airway access when endotracheal intubation cannot be performed. Supplied sterile in peel-open packages. Intended for one-time use....
Used for emergency airway access when conventional endotracheal intubation cannot be performed. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: